BioSpace News Archive

Allied Corp. (“Allied” or the “Company”) (OTCQB: ALID), an international medical cannabis company focused on creating and providing targeted cannabinoid health solutions to address today’s medical issues, today announced the appointment of Chief Financial Officer Mr. Ryan Maarschalk, Bsc, CPA.

The Vaccine & Immunotherapy Center (VIC) at Massachusetts General Hospital will continue to work with HaloVax and Hoth to Advance this Project Voltron Therapeutics, Inc., the parent of HaloVax, has an exclusive worldwide license to the SAV technology

CDISC Standards Supporting the Research Community during an Unprecedented Time

Sage Growth Partners (SGP) and Black Book Market Research today announced findings from a recently completed joint survey of U.S. healthcare consumers that assesses the public’s challenges, needs, and perspectives during the current COVID-19 pandemic.

The application seeks approval of a new, additional formulation of Xofluza as granules for oral suspension for people one year of age and older with influenza

Zyla Life Sciences (OTCQX: ZCOR) (“Zyla” or the “Company”), a commercial-stage life sciences company, today reported financial results for the fourth quarter and full year ended December 31, 2019, including net sales from commercial products: SPRIX® (ketorolac tromethamine) Nasal Spray, VIVLODEX® (meloxicam), ZORVOLEX® (diclofenac)), INDOCIN® (indomethacin) suppositories, INDOCIN® oral suspension and OXAYDO® (oxycodone HCI, USP) tablets for oral use only –CII.

Reliv International, Inc. (NASDAQ:RELV), a maker of nutritional supplements that promote optimal health, today reported its financial results for the fourth quarter and full year of 2019.

Seek Thermal, a leading provider of affordable, high-performance thermal imaging products, announces the introduction of Seek ScanTM, a simple, low-cost thermal imaging system designed to automate body temperature screening using skin temperature as a proxy.

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the year ended December 31, 2019 and provided a corporate update. “2019 was a productive year for the Company with the acquisition of ALT-801, a supplemental award for the development of NasoShield from BARDA, and the advancement of ALT-702 as a preclinical program,” said Vipin K. Garg, Ph.D., President and Chief Executive Offi

Passage Bio, Inc. today announced that management will participate in the virtual Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day on Friday, April 3, 2020. About Passage Bio Passage Bio is a genetic medicines company focused on developing transformative therapies for rare, monog